uniQure Future Growth

Future criteria checks 2/6

uniQure is forecast to grow earnings and revenue by 23.6% and 31.6% per annum respectively. EPS is expected to grow by 29.3% per annum. Return on equity is forecast to be -93.3% in 3 years.

Key information

23.6%

Earnings growth rate

29.3%

EPS growth rate

Biotechs earnings growth	0%
Revenue growth rate	31.6%
Future return on equity	-93.3%
Analyst coverage	Good
Last updated	23 Feb 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BMV:QURE N - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	154	-144	-91	-76	7
12/31/2025	133	-195	-166	-151	9
12/31/2024	64	-204	-140	-178	14
12/31/2023	15	-298	-168	28	14
9/30/2023	112	-228	-161	-151	N/A
6/30/2023	112	-187	-251	-239	N/A
3/31/2023	110	-157	-214	-198	N/A
12/31/2022	106	-127	-163	-145	N/A
9/30/2022	61	-125	-154	-137	N/A
6/30/2022	62	-114	-149	-129	N/A
3/31/2022	525	324	286	304	N/A
12/31/2021	524	330	271	288	N/A
9/30/2021	500	321	281	298	N/A
6/30/2021	500	303	292	303	N/A
3/31/2021	38	-139	-154	-143	N/A
12/31/2020	38	-125	-144	-135	N/A
9/30/2020	6	-166	-132	-124	N/A
6/30/2020	5	-136	-120	-111	N/A
3/31/2020	6	-124	-114	-105	N/A
12/31/2019	7	-124	-105	-99	N/A
9/30/2019	6	-105	-96	-91	N/A
6/30/2019	8	-103	-93	-89	N/A
3/31/2019	9	-92	-86	-81	N/A
12/31/2018	11	-83	-80	-76	N/A
9/30/2018	12	-90	-81	-76	N/A
6/30/2018	11	-78	-76	-71	N/A
3/31/2018	13	-78	-78	-74	N/A
12/31/2017	13	-79	-70	-64	N/A
9/30/2017	20	-67	-71	-62	N/A
6/30/2017	25	-72	N/A	-65	N/A
3/31/2017	24	-71	N/A	-68	N/A
12/31/2016	25	-73	N/A	-72	N/A
9/30/2016	20	-76	N/A	-81	N/A
6/30/2016	16	-90	N/A	-62	N/A
3/31/2016	14	-90	N/A	5	N/A
12/31/2015	11	-82	N/A	7	N/A
9/30/2015	8	-76	N/A	22	N/A
6/30/2015	6	-58	N/A	13	N/A
3/31/2015	5	-45	N/A	-35	N/A
12/31/2014	6	-50	N/A	-37	N/A
9/30/2014	5	-41	N/A	-29	N/A
6/30/2014	6	-42	N/A	-6	N/A
3/31/2014	6	-41	N/A	-7	N/A
12/31/2013	4	-37	N/A	-6	N/A
9/30/2013	3	-33	N/A	-1	N/A
6/30/2013	1	-27	N/A	-18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: QURE N is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QURE N is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QURE N is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QURE N's revenue (31.6% per year) is forecast to grow faster than the MX market (6.1% per year).

High Growth Revenue: QURE N's revenue (31.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: QURE N is forecast to be unprofitable in 3 years.

uniQure Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

Uniqure N.V. Announces Executive Changes

uniQure N.V., Annual General Meeting, Jun 18, 2024

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Insufficient new directors

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Insufficient new directors

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure N.V. Announces Executive Changes

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies